Submitted:
29 April 2025
Posted:
30 April 2025
You are already at the latest version
Abstract

Keywords:
1. Introduction
2. Materials and Methods
3. Ambulatory Surgery and Early Discharge Post ALND
3.1. Benefits of Ambulatory Surgery
3.2. The Role of ERAS Protocols in Facilitating Early Discharge
3.3. Early Discharge Feasibility and Alternatives to Drains
3.4. Economic Impact of Ambulatory Surgery
4. Omission of Surgical Drains in Lymphadenectomy
4.1. Types of Drainage Protocols
4.2. Use of Drains
4.3. Alternative Techniques to Reduce Seroma
4.4. Recent Scientific Evidence
5. Use of Tissue Sealants in ALDN
5.1. Types of Sealants
5.1.1. Fibrin-Based Sealants
5.1.2. Polyethylene Glycol (PEG)-Based Sealants
5.1.3. Cyanoacrylate-Based Sealants
5.1.4. Thrombin and Fibrinogen Combipatches
| Outcome | Drainage | Sealants |
| Seroma formation | Common | Variable (higher in some studies, lower in others) |
| Hospital Stay | Prolonged | Reduced in some sealant groups |
| Need for postoperative aspirations | Frequent | Reduced in some sealant groups |
| Pain and discomfort | Higher due to drains | Lower in most sealant groups |
| Cost-effectiveness | Increased outpatients’ visits | Potential cost savings |
6. Minimally Invasive and Endoscopic Surgical Approaches
6.1. Endoscopic Axillary Lymphadenectomy
6.2. Robotics and the New Frontier of Axillary Surgery
7. Breast Cancer Axillary Lymphadenectomy and Quality of Life
7.1. Introduction
7.2. Conservative Surgery of the Axilla
7.3. Quality of Life and Breast Cancer Surgery
8. Discussion
9. Limitations
10. Conclusions
11. Future Directions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
References
- A. J. M. Van Bemmel, C. J. H. Van De Velde, R. F. Schmitz, and G. J. Liefers, “Prevention of seroma formation after axillary dissection in breast cancer: A systematic review,” European Journal of Surgical Oncology, vol. 37, no. 10, pp. 829–835, 2011. [CrossRef]
- P. K. Jain, R. Sowdi, A. D. G. Anderson, and J. MacFie, “Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer,” British Journal of Surgery, vol. 91, no. 1, pp. 54–60, 2004. [CrossRef]
- J. C. Taylor, S. Rai, F. Hoar, H. Brown, and L. Vishwanath, “Breast cancer surgery without suction drainage: The impact of adopting a ‘no drains’ policy on symptomatic seroma formation rates,” European Journal of Surgical Oncology, vol. 39, no. 4, pp. 334–338, 2013. [CrossRef]
- J. Gunn, T. Gibson, Z. Li, N. Diehl, S. Bagaria, and S. McLaughlin, “Symptomatic Axillary Seroma after Sentinel Lymph Node Biopsy: Incidence and Treatment,” Ann Surg Oncol, vol. 23, no. 10, pp. 3347–3353, 2016. [CrossRef]
- Tamminen, T. Meretoja, and I. Koskivuo, “Same-day mastectomy and axillary lymph node dissection is safe for most patients with breast cancer,” J Surg Oncol, vol. 125, no. 5, pp. 831–838, 2022. [CrossRef]
- P. Karakousis, “Axillary Padding as an Alternative to Closed Suction Drain for Ambulatory Axillary Lymphadenectomy—Invited Critique,” Archives of Surgery, vol. 137, no. 2, p. 173, 2002. [CrossRef]
- Z. Al-Hilli, K. M. Thomsen, E. B. Habermann, J. W. Jakub, and J. C. Boughey, “Reoperation for Complications after Lumpectomy and Mastectomy for Breast Cancer from the 2012 National Surgical Quality Improvement Program (ACS-NSQIP),” Ann Surg Oncol, vol. 22, pp. 459–469, 2015. [CrossRef]
- M. Medarde-Ferrer et al., “Aplicación de un protocolo ERAS (enhanced recovery after surgery) para la práctica cirugía oncológica compleja de la mama en régimen ambulatorio,” Revista de Senología y Patología Mamaria, vol. 37, no. 4, p. 100614, 2024. [CrossRef]
- M. Barry, W. P. Weber, S. Lee, A. Mazzella, and L. M. Sclafani, “Enhancing the clinical pathway for patients undergoing axillary lymph node dissection,” Breast, vol. 21, no. 4, pp. 440–443, 2012. [CrossRef]
- M. Siegel, “Level I and II Axillary Dissection in the Treatment of Early-Stage Breast Cancer,” Archives of Surgery, vol. 125, no. 9, p. 1144, 1990. [CrossRef]
- J. Bonnema et al., “Cost of care in a randomised trial of early hospital discharge after surgery for breast cancer,” Eur J Cancer, vol. 34, no. 13, pp. 2015–2020, 1998. [CrossRef]
- A. Bundred N, Maguire P, Reynolds J, Grimshaw J, Morris J, Thomson L, Barr L, “Randomised controlled trial of effects of early discharge after surgery for breast cancer,” BMJ, vol. 7;317(7168, pp. 1275–9. [CrossRef]
- Holcombe, N. West, R. E. Mansel, and K. Horgan, “The satisfaction and savings of early discharge with drain in situ following axillary lymphadenectomy in the treatment of breast cancer,” European Journal of Surgical Oncology, vol. 21, no. 6, pp. 604–606, 1995. [CrossRef]
- K. Jogerst et al., “Same-Day Discharge After Mastectomy: Breast Cancer Surgery in the Era of ERAS®,” Ann Surg Oncol, vol. 27, no. 9, pp. 3436–3445, 2020. [CrossRef]
- R. G. Margolese and J. C. M. Lasry, “Ambulatory surgery for breast cancer patients,” Ann Surg Oncol, vol. 7, no. 3, pp. 181–187, 2000. [CrossRef]
- K. Horgan, E. A. Benson, A. Miller, and A. Robertson, “Early discharge with drain in situ following axillary lymphadenectomy for breast cancer,” Breast, vol. 9, no. 2, pp. 90–92, 2000. [CrossRef]
- J. M. Classe, D. Berchery, L. Campion, R. Pioud, F. Dravet, and S. Robard, “Randomized clinical trial comparing axillary padding with closed suction drainage for the axillary wound after lymphadenectomy for breast cancer,” British Journal of Surgery, vol. 93, no. 7, pp. 820–824, 2006. [CrossRef]
- V. Srivastava, S. Basu, and V. K. Shukla, “Seroma formation after breast cancer surgery: What we have learned in the last two decades,” J Breast Cancer, vol. 15, no. 4, pp. 373–380, 2012. [CrossRef]
- R. A. Droeser et al., “Volume-controlled vs no/short-term drainage after axillary lymph node dissection in breast cancer surgery: A meta-analysis,” Breast, vol. 18, no. 2, pp. 109–114, 2009. [CrossRef]
- P. K. Jain, R. Sowdi, A. D. G. Anderson, and J. MacFie, “Randomized clinical trial investigating the use of drains and fibrin sealant following surgery for breast cancer,” British Journal of Surgery, vol. 91, no. 1, pp. 54–60, 2004. [CrossRef]
- M. B. A E Cameron 1, S R Ebbs, F Wylie, “Suction drainage of the axilla: a prospective randomized trial,” Br J Surg, vol. 75(12), p. 1211, 1998. [CrossRef]
- R. G. Somers, L. K. Jablon, M. J. Kaplan, G. L. Sandler, and N. K. Rosenblatt, “The use of closed suction drainage after lumpectomy and axillary node dissection for breast cancer: A prospective randomized trial,” Ann Surg, vol. 215, no. 2, pp. 146–149, 1992. [CrossRef]
- J. Zavotsky, R. C. Jones, M. B. Brennan, and A. E. Giuliano, “Evaluation of axillary lymphadenectomy without axillary drainage for patients undergoing breast-conserving therapy,” Ann Surg Oncol, vol. 5, no. 3, pp. 227–231, 1998. [CrossRef]
- P. S. H. Soon, J. Clark, and C. J. Magarey, “Seroma formation after axillary lymphadenectomy with and without the use of drains,” Breast, vol. 14, no. 2, pp. 103–107, 2005. [CrossRef]
- X. D. He, Z. H. Guo, J. H. Tian, K. H. Yang, and X. D. Xie, “Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials,” Medical Oncology, vol. 28, no. SUPPL. 1, pp. 22–30, 2011. [CrossRef]
- M. S. Troost, C. J. Kempees, and M. A. J. De Roos, “Breast cancer surgery without drains: No influence on seroma formation,” International Journal of Surgery, vol. 13, pp. 170–174, 2015. [CrossRef]
- J. C. Taylor, S. Rai, F. Hoar, H. Brown, and L. Vishwanath, “Breast cancer surgery without suction drainage: The impact of adopting a ‘no drains’ policy on symptomatic seroma formation rates,” European Journal of Surgical Oncology, vol. 39, no. 4, pp. 334–338, 2013. [CrossRef]
- S. López Gordo et al., “Seroma control in axillary lymphadenectomy with Glubran 2® without drain. Multicenter, prospective, randomized, clinical trial. GALA-ND study (Glubran, Axillary Lymphadenectomy, Ambulatory, No Drain),” Trials, vol. 25, no. 1, pp. 1–12, 2024. [CrossRef]
- S. S. Jeffrey, W. H. Goodson, D. M. Ikeda, R. L. Birdwell, and M. S. Bogetz, “Axillary Lymphadenectomy for Breast Cancer Without Axillary Drainage,” Archives of Surgery, vol. 130, no. 8, pp. 909–913, 1995. [CrossRef]
- J. R. Garbay et al., “Axillary padding without drainage after axillary lymphadenectomy - A prospective study of 299 patients with early breast cancer,” Breast Care, vol. 7, no. 3, pp. 231–235, 2012. [CrossRef]
- Conversano et al., “Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma,” Clin Breast Cancer, vol. 17, no. 4, pp. 293–297, 2017. [CrossRef]
- D. Purushotham et al., “Randomized clinical trial of no wound drains and early discharge in the treatment of women with breast cancer,” British Journal of Surgery, vol. 89, no. 3, pp. 286–292, 2002. [CrossRef]
- T. Cortadellas et al., “Electrothermal bipolar vessel sealing system in axillary dissection: A prospective randomized clinical study,” International Journal of Surgery, vol. 9, no. 8, pp. 636–640, 2011. [CrossRef]
- Lumachi, S. M. M. Basso, D. A. Santeufemia, M. Bonamini, and G. B. Chiara, “Ultrasonic dissection system technology in breast cancer: A case-control study in a large cohort of patients requiring axillary dissection,” Breast Cancer Res Treat, vol. 142, no. 2, pp. 399–404, 2013. [CrossRef]
- D. Thomson DR, Sadideen H, “Wound drainage after axillary dissection for carcinoma of the breast.,” Syst Rev, vol. 20;2013(10. [CrossRef]
- E. Buch-Villa et al., “Clinical and cost outcomes of a polyethylene glycol (PEG)-coated patch versus drainage after axillary lymph node dissection in breast cancer: results from a multicentre randomized clinical trial,” British Journal of Surgery, vol. 110, no. 9, pp. 1180–1188, 2023. [CrossRef]
- Sierra DH., “Fibrin Sealant Adhesive Systems: A Review of Their Chemistry, Material Properties and Clinical Applications,” J Biomater Appl, vol. 7 (4), pp. 309–352, 1993. [CrossRef]
- M. Moore et al., “Fibrin sealant reduces the duration and amount of fluid drainage after axillary dissection: A randomized prospective clinical trial,” J Am Coll Surg, vol. 192, no. 5, pp. 591–599, 2001. [CrossRef]
- N. Gilly, Y. François, A. C. Sayag-Beaujard, O. Glehen, A. Brachet, and J. Vignal, “Prevention of lymphorrhea by means of fibrin glue after axillary lymphadenectomy in breast cancer: Prospective randomized trial,” European Surgical Research, vol. 30, no. 6, pp. 439–443, 1998. [CrossRef]
- R. Ruggiero et al., “Axillary lymphadenectomy for breast cancer and fibrin glue,” Ann Ital Chir, vol. 85, no. 1, pp. 88–92, 2014.
- P. K. Mustonen, M. A. Härmä, and M. J. Eskelinen, “THE EFFECT OF FIBRIN SEALANT COMBINED WITH FIBRINOLYSIS INHIBITOR ON REDUCING THE AMOUNT OF LYMPHATIC LEAKAGE AFTER AXILLARY EVACUATION IN BREAST CANCER A prospective randomized clinical trial Background and Aims : One third of women undergoing mastectomy,” no. 1, pp. 209–212, 2004.
- JF. Vaxman F, Kolbe A, Stricher F, Zund D, Volkmar P, Gros D, “Does fibrin glue improve drainage after axillary lymph node dissection? Prospective and randomized study in humans.,” Eur Surg Res., vol. 27(5), pp. 346–52, 1995.
- R. Benevento et al., “The effects of low-thrombin fibrin sealant on wound serous drainage, seroma formation and length of postoperative stay in patients undergoing axillary node dissection for breast cancer: A randomized controlled trial,” International Journal of Surgery, vol. 12, no. 11, pp. 1210–1215, 2014. [CrossRef]
- Y. T. Chang, S. L. Shih, E. W. Loh, and K. W. Tam, “Effects of Fibrin Sealant on Seroma Reduction for Patients with Breast Cancer Undergoing Axillary Dissection: Meta-Analysis of Randomized Controlled Trials,” Ann Surg Oncol, vol. 27, no. 13, pp. 5286–5295, 2020. [CrossRef]
- K. Vasileiadou, C. Kosmidis, G. Anthimidis, S. Miliaras, I. Kostopoulos, and E. Fahantidis, “Cyanoacrylate Adhesive Reduces Seroma Production After Modified Radical Mastectomy or Quadrantectomy With Lymph Node Dissection—A Prospective Randomized Clinical Trial,” Clin Breast Cancer, vol. 17, no. 8, pp. 595–600, 2017. [CrossRef]
- E. Esposito et al., “Cyanoacrylate glue in breast surgery: the GLUBREAST Trial,” Front Oncol, vol. 14, no. January, pp. 1–10, 2024. [CrossRef]
- M. Al-Masri et al., “Effectiveness of Cyanoacrylate in Reducing Seroma Formation in Breast Cancer Patients Post-Axillary Dissection: A Randomized Controlled Trial,” Front Oncol, vol. 10, no. January, pp. 1–8, 2021. [CrossRef]
- Z. Clement, P. Shin, C. Hoffmann, M. Eaton, and W. McLeay, “A Double-Blinded Prospective Randomised Controlled Trial to Assess the Efficacy of Glubran-2 in Reducing Seroma Formation after a Mastectomy with or without Axillary Dissection,” Adv Breast Cancer Res, vol. 06, no. 04, pp. 117–128, 2017. [CrossRef]
- M. Vinchant et al., “Intérêt d’un combipatch de thrombine et de fibrinogène dans la prévention des lymphocèles après curage axillaire,” Gynecologie Obstetrique et Fertilite, vol. 41, no. 10, pp. 583–587, 2013. [CrossRef]
- Lacoste, L. Ouldamer, G. Body, and H. Marret, “Does the use of TachoSil allow to reduce the morbidity of axillary dissection?,” Gynecologie Obstetrique et Fertilite, vol. 41, no. 2, pp. 141–143, 2013. [CrossRef]
- N. Tagaya and K. Kubota, “Experience with endoscopic axillary lymphadenectomy using needlescopic instruments in patients with breast cancer: A preliminary report,” Surgical Endoscopy and Other Interventional Techniques, vol. 16, no. 2, pp. 307–309, 2002. [CrossRef]
- Xiong et al., “Contrast of Mastoscopic and Conventional Axillary Lymph Node Dissection of Patients With Breast Cancer: Meta-Analysis,” Cancer Control, vol. 27, no. 2, pp. 1–8, 2020. [CrossRef]
- B. Suzanne F, Emering C, Wattiez A, Bournazeau JA, Bruhat MA, “Le curage axillaire par lipo-aspiration et prélèvement endoscopique. A propos de 72 cas [Axillary lymphadenectomy by lipo-aspiration and endoscopic picking. Apropos of 72 cases].,” Chirurgie, vol. 122(2), pp. 138–42, 1997.
- B. Cangiotti L, Poiatti R, Taglietti L, Re P, “A mini-invasive technique for axillary lymphadenectomy in early breast cancer: a study of 15 patients,” J Exp Clin Cancer Res, vol. (3), no. 295–8, 1999.
- S. Kamprath, J. Bechler, R. Kühne-Heid, N. Krause, and A. Schneider, “Endoscopic axillary lymphadenectomy without prior liposuction: Development of a technique and initial experience,” Surg Endosc, vol. 13, no. 12, pp. 1226–1229, 1999. [CrossRef]
- Z. H. Wang et al., “Single-port endoscopic-sentinel lymph node biopsy combined with indocyanine green and carbon nanoparticles in breast cancer,” Surg Endosc, vol. 37, no. 10, pp. 7591–7599, 2023. [CrossRef]
- cai Yao, C. Liu, and J. Xian, “Comparison of single-pore non-liposuction near-infrared laparoscopy with conventional open surgery for axillary sentinel lymph node biopsy in patients with early breast cancer: a single-center, small-sample retrospective study,” World J Surg Oncol, vol. 21, no. 1, pp. 1–8, 2023. [CrossRef]
- M. E. Aponte-Rueda, R. A. Saade Cárdenas, and M. J. Saade Aure, “Endoscopic axillary dissection: A systematic review of the literature,” Breast, vol. 18, no. 3, pp. 150–158, 2009. [CrossRef]
- R. L. De Wilde, E. H. Schmidt, M. Hesseling, R. Mildner, V. Frank, and M. Tenger, “Comparison of classic and endoscopic lymphadenectomy for staging breast cancer,” Journal of the American Association of Gynecologic Laparoscopists, vol. 10, no. 1, pp. 75–79, 2003. [CrossRef]
- C. Luo et al., “Comparison of mastoscopic and conventional axillary lymph node dissection in breast cancer: Long-term results from a randomized, multicenter trial,” Mayo Clin Proc, vol. 87, no. 12, pp. 1153–1161, 2012. [CrossRef]
- S. López Gordo et al., “Indocyanine green for axillary sentinel lymph node biopsy in patients with breast cancer (INSEAN study),” Cir Esp, 2025. [CrossRef]
- Chengyu et al., “A standardized surgical technique for mastoscopic axillary lymph node dissection,” Surg Laparosc Endosc Percutan Tech, vol. 15, no. 3, pp. 153–159, 2005. [CrossRef]
- J. H. Ahn et al., “Early experience of robotic axillary lymph node dissection in patients with node-positive breast cancer,” Breast Cancer Res Treat, vol. 198, no. 3, pp. 405–412, 2023. [CrossRef]
- Chen et al., “Efficacy of da Vinci robot-assisted lymph node surgery than conventional axillary lymph node dissection in breast cancer – A comparative study,” International Journal of Medical Robotics and Computer Assisted Surgery, vol. 17, no. 6, pp. 1–9, 2021. [CrossRef]
- Basch, P. Torda, and K. Adams, “Standards for patient-reported outcome-based performance measures,” Jul. 10, 2013. [CrossRef]
- E. Giuliano et al., “Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial,” JAMA - Journal of the American Medical Association, vol. 318, no. 10, pp. 918–926, Sep. 2017. [CrossRef]
- E. Giuliano et al., “Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial,” JAMA - Journal of the American Medical Association, vol. 305, no. 6, pp. 569–575, Feb. 2011. [CrossRef]
- Donker et al., “Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial,” Lancet Oncol, vol. 15, no. 12, pp. 1303–1310, Nov. 2014. [CrossRef]
- J. C. Boughey et al., “Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: The ACOSOG Z1071 (alliance) clinical trial,” JAMA - Journal of the American Medical Association, vol. 310, no. 14, pp. 1455–1461, 2013. [CrossRef]
- T. Kuehn et al., “Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): A prospective, multicentre cohort study,” Lancet Oncol, vol. 14, no. 7, pp. 609–618, Jun. 2013. [CrossRef]
- J. F. Boileau et al., “Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: The SN FNAC study,” Journal of Clinical Oncology, vol. 33, no. 3, pp. 258–263, Jan. 2015. [CrossRef]
- S. Caudle et al., “Improved axillary evaluation following neoadjuvant therapy for patientswith node-positive breast cancer using selective evaluation of clipped nodes: Implementation of targeted axillary dissection,” Journal of Clinical Oncology, vol. 34, no. 10, pp. 1072–1078, Apr. 2016. [CrossRef]
- S. Alvarez-Pardo et al., “Quality of Life in Breast Cancer Survivors in Relation to Age, Type of Surgery and Length of Time since First Treatment,” Int J Environ Res Public Health, vol. 19, no. 23, Dec. 2022. [CrossRef]
- Marinkovic, N. Djordjevic, L. Djordjevic, N. Ignjatovic, M. Djordjevic, and V. Karanikolic, “Assessment of the quality of life in breast cancer depending on the surgical treatment,” Supportive Care in Cancer, vol. 29, no. 6, pp. 3257–3266, Jun. 2021. [CrossRef]
- D. Smith et al., “Long-Term Quality of Life in Patients with Breast Cancer after Breast Conservation vs Mastectomy and Reconstruction,” JAMA Surg, vol. 157, no. 6, Jun. 2022. [CrossRef]
- U. Boehmer, M. Glickman, M. Winter, and M. A. Clark, “Long-term breast cancer survivors’ symptoms and morbidity: Differences by sexual orientation?,” Journal of Cancer Survivorship, vol. 7, no. 2, pp. 203–210, Jun. 2013. [CrossRef]
- Laws et al., “Long-Term Patient-Reported Arm Symptoms in Breast Cancer Survivors,” Ann Surg Oncol, vol. 31, no. 3, pp. 1623–1633, Mar. 2024. [CrossRef]
- M. Enien, N. Ibrahim, W. Makar, D. Darwish, and M. Gaber, “Health-related quality of life: Impact of surgery and treatment modality in breast cancer,” J Cancer Res Ther, vol. 14, no. 5, pp. 957–963, Jul. 2018. [CrossRef]
- M. Kool et al., “Long term effects of extended adjuvant endocrine therapy on quality of life in breast cancer patients,” Breast, vol. 24, no. 3, pp. 224–229, Jun. 2015. [CrossRef]
- Hopwood, J. Haviland, J. Mills, G. Sumo, and J. M Bliss, “The impact of age and clinical factors on quality of life in early breast cancer: An analysis of 2208 women recruited to the UK START Trial (Standardisation of Breast Radiotherapy Trial),” Breast, vol. 16, no. 3, pp. 241–251, Jun. 2007. [CrossRef]
- Barranger, G. Dubernard, J. Fleurence, M. Antoine, E. Darai, and S. Uzan, “Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer,” J Surg Oncol, vol. 92, no. 1, pp. 17–22, Oct. 2005. [CrossRef]
- S. A. L. Bartels et al., “Radiotherapy or Surgery of the Axilla after a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial,” Journal of Clinical Oncology, vol. 41, no. 12, pp. 2159–2165, Apr. 2023. [CrossRef]
- R. Belmonte, O. Garin, M. Segura, A. Pont, F. Escalada, and M. Ferrer, “Quality-of-life impact of sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients,” Value in Health, vol. 15, no. 6, pp. 907–915, Sep. 2012. [CrossRef]
- T. S. Dabakuyo et al., “A multicenter cohort study to compare quality of life in breast cancer patients according to sentinel lymph node biopsy or axillary lymph node dissection,” Annals of Oncology, vol. 20, no. 8, pp. 1352–1361, 2009. [CrossRef]
- Del Bianco et al., “Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: Results of the sentinella-GIVOM Italian randomised clinical trial,” European Journal of Surgical Oncology, vol. 34, no. 5, pp. 508–513, May 2008. [CrossRef]
- J. J. Kootstra et al., “A longitudinal comparison of arm morbidity in stage I-II breast cancer patients treated with sentinel lymph node biopsy, sentinel lymph node biopsy followed by completion lymph node dissection, or axillary lymph node dissection,” Ann Surg Oncol, vol. 17, no. 9, pp. 2384–2394, Sep. 2010. [CrossRef]
- M. Al Nakib et al., “Quality of life at 2 years follow-up after sentinel lymph node biopsy, immediate or delayed axillary dissection for breast cancer,” Sep. 2010, Breast J. [CrossRef]
- J. S. Rietman et al., “Long term treatment related upper limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II breast cancer,” European Journal of Surgical Oncology, vol. 32, no. 2, pp. 148–152, Mar. 2006. [CrossRef]

| Study/ year | Patients N | Pain | arm swelling | Dysesthesias | QoL |
| Barranger E et al 2005 | SNB n54 ALND n61 SNB + ALND 10 |
21,2% 52,9% 60% |
0% 21,6% 10% |
5.7% 51% 50% |
7.6 7.6 7.7 |
| Belmonte et al 2012 | SNB n 64 ALND n 29 |
ND | 11.8% 35.5% |
9.8% 69.2% |
119.05 111.89 |
| Dabakuyoet al 2009 | SNB n 222 ALND n235 SNB + ALND n61 |
ND | ND | ND | 75.9 74.5 68.0 |
| Al Nakib el al 2010 | SNB 212 ALND 131 |
39.4% 67.7% |
9.9% 33.6% |
40.1% 83.1% |
73.6 68.8 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).